Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Regeneron Pharmaceuticals Inc.’s stock rose 4.9% Tuesday to put it on track for its biggest one-day gain in almost two years, ...

News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results , with sales up 10.3% year on year to $3.79 billion. Its ...

If you purchased or acquired securities in Regeneron between November 2, 2023 and October 30, 2024 and would like to discuss ...

Regeneron beat Q4 estimates with $12.07 EPS and $3.79B in sales. The company announced a dividend, a $3 billion buyback, and continued R&D investments.

NEW YORK, NY / ACCESS Newswire / February 4, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...

Regeneron Pharmaceuticals is stepping up its shareholder returns with the launch of a quarterly dividend and a $3 billion increase to its stock-buyback program. Regeneron on Tuesday said its board ...

On a per-share basis, the Tarrytown, New York-based company said it had profit of $8.06. Earnings, adjusted for stock option expense and non-recurring costs, were $12.07 per share. The results beat ...